DFDA

Sorafenib

Treatment for Liver Cancer Due To Hepatitis B

Typical Dosage: 400 mg orally twice daily

Effectiveness
70%
Safety Score
30%
Clinical Trials
15
Participants
2.5K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
30
DangerousModerateSafe
Treatment Details
Dosage Range
400 mg orally twice daily
Time to Effect
1-3 months
Treatment Duration
until disease progression or unacceptable toxicity
Evidence Quality
HIGH
Number Needed to Treat (NNT)
12(Treat 12 patients to see 1 additional successful outcome)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$150,000
Monitoring:$15,000
Side Effect Mgmt:$5,000
Total Annual:$170,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POOR
ICER
$180,000/QALY
QALYs Gained
0.4
Outcome-Based Costs
Cost per Responder
$5,666,667
Comparison vs Best Supportive Care
Cost Difference
+$170,000/year
More expensive
QALY Difference
+0.40 QALYs
Better outcomes
Dominance
No dominance
Sorafenib Outcomes

for Liver Cancer Due To Hepatitis B

Efficacy Outcomes
Overall Effectiveness
+70%
Response Rate
+3%
Remission Rate
+1%
Common Side Effects
Diarrhea
+55%
Palmar-plantar erythrodysesthesia (PPE)
+45%
Fatigue
+44%
Rash
+39%
Hypertension
+11%

Sources:

nih.gov
nih.gov
nih.gov

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
No active trials currently recruiting for this treatment

No active trials found in ClinicalTrials.gov